Cerebral embolic protection devices during transcatheter aortic valve implantation, the current state of the art.
Onur Sinan DeveciSercan OkutucuSefik Gorkem FatihogluAli OtoPublished in: Acta cardiologica (2021)
Stroke after transcatheter aortic valve (TAVI) is a devastating adverse event. The majority of these occur in the acute phase following TAVI where cerebral embolic events are frequent. Cerebral embolic protection devices (CEPD) have been developed to minimise the risk of peri-procedural ischaemic stroke during TAVI. CEPD have the potential to lower intraprocedural burden of new silent ischaemic brain injury. Several CEPD have been developed, but their clinical benefit remains unknown. Herein, we aimed to review the impact of the use of CEPD, in patients undergoing TAVI, on the reduction of strokes or the onset of new ischaemic lesions.
Keyphrases
- transcatheter aortic valve implantation
- aortic valve
- subarachnoid hemorrhage
- brain injury
- cerebral ischemia
- aortic valve replacement
- aortic stenosis
- transcatheter aortic valve replacement
- patients undergoing
- atrial fibrillation
- ejection fraction
- emergency department
- heart failure
- risk assessment
- human health
- coronary artery disease
- left ventricular
- adverse drug
- cerebral blood flow
- drug induced